What you need to know about Axial Spondyloarthritis (including Ankylosing Spondylitis) for clinical practice and your board exams. In Part 1, we will explore important Background, Epidemiology, Pathophysiology, Clinical Presentation, Work-up, Classification and more!

Part 2 of 2 will outline the treatment of Axial Spondyloarthritis/Ank Spond.

• 1:50 - Terminology
• 6:00 - Epidemiology
• 9:39 - Pathophysiology
• 17:10 - Clinical presentation
• 28:05 - Patient case
• 31:35 - Physical exam
• 43:00 - Work up
• 59:15 - Classification criteria
• 63:47 - Differential diagnosis
• 68:07 - Bone marrow edema on MRI

What you need to know about uveitis for your clinical practice and rheumatology board exams.

This includes what uveitis actually is, how to think about/classify uveitis in your mind (anatomically; infectious vs non-infectious; systemic vs eye-limited), causes of uveitis, the clinical presentation, workup, management and some extra stuff. As always, "Quiz Time’s” are scattered through the episode to check your understanding.

Survey link: https://docs.google.com/forms/d/e/1FAIpQLSd6QbrO0kJDzRE8t4fZPIFw1CA9nTw6Qk3Z1FVmCRpt8EdLSg/viewform?usp=sf_link

What you need to know about Still’s Disease (formerly Adult Onset Still’s Disease/Systemic JIA) for clinical practice and your board exams. 

Please help make the show better! Fill out the feedback survey at: https://docs.google.com/forms/d/e/1FAIpQLSd6QbrO0kJDzRE8t4fZPIFw1CA9nTw6Qk3Z1FVmCRpt8EdLSg/viewform?usp=sf\_link

The fundamentals of what you need for patient encounters and your boards.

In this episode we’ll exclusively discuss the management of systemic sclerosis. This includes treatment of the skin, esophageal disease, interstitial lung disease, pulmonary arterial hypertension and scleroderma renal crisis. 

Thank you for taking a couple minutes to do the survey :) 

Survey link here: https://docs.google.com/forms/d/e/1FAIpQLSd6QbrO0kJDzRE8t4fZPIFw1CA9nTw6Qk3Z1FVmCRpt8EdLSg/viewform?usp=sf_link

The fundamentals of what you need for your patient encounters and board exams. In this episode we’ll discuss a little epidemiology and pathophys, but focus heavily on the clinical presentation and workup. Part 2 will come out soon and focus on the management of systemic sclerosis. 

Thank you for taking a couple minutes to do the survey :) 

Survey link here: https://docs.google.com/forms/d/e/1FAIpQLSd6QbrO0kJDzRE8t4fZPIFw1CA9nTw6Qk3Z1FVmCRpt8EdLSg/viewform?usp=sf_link

How to manage gout! During the flare, urate lowering therapy, anti-inflammatory prophylaxis, dietary recommendations, managing gout with chronic kidney disease and lots more.

Special shoutout to Cornell’s gout king, Dr. Ted Fields, for teaching us about gout during fellowship. Some of the ideas you’ll hear today, I've learned from him.

Lastly, please fill out the short survey! Link: https://docs.google.com/forms/d/e/1FAIpQLSd6QbrO0kJDzRE8t4fZPIFw1CA9nTw6Qk3Z1FVmCRpt8EdLSg/viewform?usp=sf_link

We’ll focus on everything you need to know, short of management. This means pathophys, epidemiology, clinical presentation, workup and diagnosis.

Quiz Times can be found at:

• 15:28
• 25:30
• 35:20
• 37:35

Please do the survey! Link here: https://docs.google.com/forms/d/e/1FAIpQLSd6QbrO0kJDzRE8t4fZPIFw1CA9nTw6Qk3Z1FVmCRpt8EdLSg/viewform?usp=sf_link

What you need to know about the Antiphospholipid Syndrome for your boards and clinical practice. We’ll discuss a little pathophysiology and epidemiology, but mostly focus on the clinical presentation, workup and management, as well as Catastrophic APS (CAPS). 

Feedback survey link: https://forms.gle/QfoWGAgtcUWWVjyB8

Episode #2 of a 2-part series. Part 2 is all about how to handle specific scenarios and clinical pearls. We delve into methotrexate optimization, what to do when therapy fails, the safety of JAK inhibitors, pregnancy management in RA, DMARDs and malignancy, palindromic rheumatism, perioperative management, biosimilars and more.

Episode #1 of a 2-part series. Part 1 will provide a rundown of the guidelines and the most important drugs in the treatment of rheumatoid arthritis. Part 2 will be published shortly after.